[{"address1": "Clarendon House", "address2": "2 Church Street", "city": "Hamilton", "zip": "HM 11", "country": "Bermuda", "website": "https://www.kiniksa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.", "fullTimeEmployees": 297, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sanj K. Patel", "age": 54, "title": "CEO & Chairman of the Board", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1573081, "exercisedValue": 0, "unexercisedValue": 15634234}, {"maxAge": 1, "name": "Mr. Carsten  Boess", "age": 57, "title": "Executive Vice President of Corporate Affairs", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Martina  Struck", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.86, "open": 17.71, "dayLow": 17.53, "dayHigh": 18.11, "regularMarketPreviousClose": 17.86, "regularMarketOpen": 17.71, "regularMarketDayLow": 17.53, "regularMarketDayHigh": 18.11, "beta": 0.302, "trailingPE": 135.46155, "forwardPE": 32.01818, "volume": 476277, "regularMarketVolume": 476277, "averageVolume": 374393, "averageVolume10days": 394450, "averageDailyVolume10Day": 394450, "bid": 17.57, "ask": 17.66, "bidSize": 100, "askSize": 100, "marketCap": 1249239296, "fiftyTwoWeekLow": 10.645, "fiftyTwoWeekHigh": 22.09, "priceToSalesTrailing12Months": 4.1396794, "fiftyDayAverage": 19.2751, "twoHundredDayAverage": 17.7065, "currency": "USD", "enterpriseValue": 1049417536, "profitMargins": 0.02866, "floatShares": 29519198, "sharesOutstanding": 40304400, "sharesShort": 3643645, "sharesShortPriorMonth": 2867473, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0514, "heldPercentInsiders": 0.03931, "heldPercentInstitutions": 0.89606005, "shortRatio": 9.94, "shortPercentOfFloat": 0.1174, "impliedSharesOutstanding": 70939200, "bookValue": 6.228, "priceToBook": 2.827553, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 8650000, "trailingEps": 0.13, "forwardEps": 0.55, "pegRatio": 1.22, "enterpriseToRevenue": 3.478, "enterpriseToEbitda": -37.198, "52WeekChange": 0.6381395, "SandP52WeekChange": 0.21080327, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KNSA", "underlyingSymbol": "KNSA", "shortName": "Kiniksa Pharmaceuticals, Ltd.", "longName": "Kiniksa Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1527255000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7ea20e71-749b-31b8-994b-79f75933ead7", "messageBoardId": "finmb_558211765", "gmtOffSetMilliseconds": -14400000, "currentPrice": 17.61, "targetHighPrice": 32.0, "targetLowPrice": 28.0, "targetMeanPrice": 30.0, "targetMedianPrice": 30.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 206371008, "totalCashPerShare": 2.922, "ebitda": -28211750, "totalDebt": 12258000, "totalRevenue": 301772000, "debtToEquity": 2.793, "revenuePerShare": 4.294, "revenueGrowth": 0.652, "grossMargins": 0.64877, "ebitdaMargins": -0.09349, "operatingMargins": -0.20714001, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]